Viking Global Investors LP recently announced the acquisition of new stake in NewAmsterdam Pharma Company NV (NASDAQ:NAMS). The institutional investor has increased its shareholding in the Healthcare company by 22.99% to 8.02 million shares with purchase of 1.5 million shares. This fresh investment now brings its stake to 9.75% valued currently at $89.63 million. In addition, Millennium Management LLC raised its holdings by 0.67 million to 1.04 million shares.
With over 0.48 million NewAmsterdam Pharma Company NV (NAMS) shares trading Friday and a closing price of $17.53 on the day, the dollar volume was approximately $8.42 million. The shares have shown a positive half year performance of 46.57% and its price on 01/12/24 gained nearly 2.45%. Currently, there are 81.56M common shares owned by the public and among those 32.84M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in NewAmsterdam Pharma Company NV are AXA Framlington Biotech Fund, Polar Capital Funds Plc – Biotech, and Fidelity Nasdaq Composite Index F. AXA Framlington Biotech Fund owns 0.27 million shares of the company’s stock, all valued at over $3.03 million. The company bought an additional 0.27 million shares recently to bring their total holdings to about 0.33% of the shares outstanding. Polar Capital Funds Plc – Biotech bought 0.23 million shares to see its total holdings expand to 0.25 million shares valued at over $2.79 million and representing 0.30% of the shares outstanding. Fidelity Nasdaq Composite Index F bought 5516.0 shares to bring its total holdings to over 47324.0 shares at a value of $0.53 million. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.06% of the shares outstanding.
Shares of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) opened at $16.80, down -$0.31 from a prior closing price of $17.11. The company’s stock has a 5-day price change of 38.85% and 145.17% over the past three months. NAMS shares are trading 56.94% year to date (YTD), with the 12-month market performance up to 56.38% higher. It has a 12-month low price of $5.63 and touched a high of $18.70 over the same period. NAMS has an average intraday trading volume of 131.45K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 47.42%, 65.10%, and 56.36% respectively.
Institutional ownership of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) shares accounts for 30.03% of the company’s 81.56M shares outstanding. Mutual fund holders own 27.43%, while other institutional holders and individual stakeholders account for 29.30% and 0.73% respectively.
It has a market capitalization of $1.44B and a beta (3y monthly) value of -0.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.98% over the week and 9.30% over the month.
Analysts forecast that NewAmsterdam Pharma Company NV (NAMS) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$2.12 for 2023. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Earnings per share for the fiscal year are expected to decrease by -104.50%, and 21.03% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate NewAmsterdam Pharma Company NV (NAMS) as a “Strong Buy” at a consensus score of 1.00. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NAMS, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on October 30, 2023, with the firm’s price target at $25.
